TLTFF OTC

Theralase Technologies Inc., founded in Toronto, Canada in 1994, is a clinical-stage pharmaceutical company focused on the development of innovative therapies and medical devices. The company's pharmaceutical division specializes in the research and development of photo dynamic compounds (PDCs) and their drug formulations. These advanced treatments are designed to combat cancer, bacterial infections, and viral diseases, with Theralase's operations spanning Canada, the United States, and other international regions. A significant drug candidate, TLD-1433, is presently in Phase II clinical trials for the treatment of Bacillus Calmette Guérin-unresponsive Carcinoma In-Situ non-muscle invasive bladder cancer. Demonstrating a broader commitment to public health, the company also holds research agreements with the University of Manitoba's Medical Microbiology department for the development of coronavirus vaccines and therapies, and collaborates with the National Microbiology Laboratory and Public Health Agency of Canada on a Canadian-based SARS-CoV-2 vaccine. In parallel with its drug pipeline, Theralase engineers, manufactures, and markets patented super-pulsed laser technology. This medical device is primarily used to alleviate chronic knee pain and is also applied off-label for a variety of nerve, muscle, and joint conditions. Its product line features the TLC-2000, a superpulsed visible red laser that promotes healing by reducing pain and inflammation while adhering to the Maximal Permissible Exposure limit for tissue, along with related accessories. Additionally, the company provides a suite of controller-less cool laser therapy systems, including the TLC-900, TLC-300, and TLC-100. Theralase's products are sold directly to healthcare practitioners.